Cholinergic precursors in the treatment of cognitive impairment of vascular origin: Ineffective approaches or need for re-evaluation?

@article{Parnetti2007CholinergicPI,
  title={Cholinergic precursors in the treatment of cognitive impairment of vascular origin: Ineffective approaches or need for re-evaluation?},
  author={Lucilla Parnetti and Fiorenzo Mignini and Daniele Tomassoni and Enea Traini and Francesco Amenta},
  journal={Journal of the Neurological Sciences},
  year={2007},
  volume={257},
  pages={264-269}
}
Choline alphoscerate pharmacology and its role in the treatment of cognitive impairment related to neurological disorders
TLDR
Preliminary evaluations suggest a useful role for choline alphoscerate in patients with cognitive impairment of varying severity related to brain trauma or to Parkinson’s disease, and literature data suggest that, in these conditions, the semi-synthetic compound shows a better efficacy than other cholinergic precursors and has a good tolerability and safety profile.
Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment
TLDR
A brief overview of the cholinergic treatment strategy for VaD and its relevant mechanisms of anti-inflammation is provided.
Association Between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in the Treatment of Depression in Patients with Alzheimer’s Disease
TLDR
Depression symptoms of Alzheimer’s disease patients in the mild to moderate stage probably could to benefit of a stronger cholinergic stimulation induced by associating donepezil with the cholinesterase inhibitor choline alphoscerate.
Mild cognitive impairment of vascular origin: Proposal for an empirical approach in primary care
TLDR
This review outlines various attitudes and therapeutic possibilities that might be useful in the scope of Primary Care.
Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review
TLDR
From the data reported in the literature, it emerges that nootropics may be an effective alternative for strengthening and enhancing cognitive performance in patients with a range of pathologies.
The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer's Disease) Trial: interim results after two years of treatment.
TLDR
Findings suggest that the combination of choline alphoscerate with a ChE-I may prolong/increase the effectiveness of cholinergic therapies in AD with concomitant ischemic cerebrovascular injury.
...
...

References

SHOWING 1-10 OF 40 REFERENCES
Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data
Galantamine for vascular cognitive impairment.
  • D. Craig, J. Birks
  • Medicine, Psychology
    The Cochrane database of systematic reviews
  • 2006
TLDR
The data available at the time of review suggest some advantage over placebo in the areas of cognition and executive functioning in one trial but this was not seen in a second trial which included smaller numbers of relevant patients, and more studies are needed before firm conclusions can be drawn.
Cholinesterase inhibitors for Alzheimer's disease.
  • J. Birks
  • Medicine
    The Cochrane database of systematic reviews
  • 2006
TLDR
Treatment for periods of 6 months and one year, with donepezil, galantamine or rivastigmine at the recommended dose for people with mild, moderate or severe dementia due to Alzheimer's disease produced improvements in cognitive function, on average -2.7 points, in the midrange of the 70 point ADAS-Cog Scale.
Lecithin for dementia and cognitive impairment.
TLDR
Evidence from randomized trials does not support the use of lecithin in the treatment of patients with dementia, and results from the small trials to date do not indicate priority for a large randomized trial.
Cholinergic dysfunction in vascular dementia
  • G. Román
  • Medicine, Biology
    Current psychiatry reports
  • 2005
TLDR
Evidence is presented indicating the occurrence of cholinergic dysfunction in VaD, independent from AD, and controlled clinical trials of cholinesterase inhibitors (ChEIs) inVaD and in patients with AD plus cerebrovascular disease are reviewed.
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials
TLDR
The scientific basis for recommendations of cholinesterase inhibitors for the treatment of Alzheimer's disease is questionable because of flawed methods and small clinical benefits.
Rivastigmine for subcortical vascular dementia
  • G. Román
  • Psychology, Medicine
    Expert review of neurotherapeutics
  • 2005
TLDR
Small open-label studies of patients with subcortical vascular dementia showed that rivastigmine improved attention, executive function, apathy and other behavioral deficits, making it a promising agent in vascular dementia but its effects remain to be established in double-blind, placebo-controlled clinical trials.
The Cholinergic Hypothesis: A Historical Overview, Current Perspective, and Future Directions
TLDR
The Cholinergic hypothesis asserts that significant, functional disturbances in cholinergic activity occur in the brains of aged and especially demented patients, these disturbances play an important role in the memory loss and related cognitive problems associated with old age and dementia, and proper enhancement or restoration of cholinergy function may significantly reduce the severity of the cognitive loss.
...
...